Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Gadoquatrane 0.03 mmol Gd/kg · 1 trial · 2 indications
Including severity of TEAE
| Arm | Type | Description |
|---|---|---|
| 0.03 mmol Gd/kg BAY1747846 and matching placebo | EXPERIMENTAL | 12 healthy male participants were planned to be enrolled into this arm, 9 on BAY1747846 and 3 on placebo |
| 0.1 mmol Gd/kg BAY1747846 and matching placebo | EXPERIMENTAL | 12 healthy male participants were planned to be enrolled into this arm, 9 on BAY1747846 and 3 on placebo |
| Name | Type | Description |
|---|---|---|
| Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg | DRUG | 0.03 mmol Gd/kg by intravenous injection (at 2 mL/s) |
| Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg | DRUG | 0.1 mmol Gd/kg by intravenous injection (at 2 mL/s) |
| Matching placebo | DRUG | 0.9% sodium chloride by intravenous injection (at 2 mL/s) |
Inclusion Criteria: * Signed informed consent prior to any study specific tests or procedures * Chinese male between 18 and 45 years (inclusive) at screening visit * Body mass index (BMI): 18.5 to 30.0 kg/m² (inclusive) * Body weight (bw): 50 to 90 kg (inclusive) * Participants of reproductive pote...
Gadoquatrane 0.03 mmol Gd/kg is used for contrast enhancement in magnetic resonance imaging (MRI). It is an investigational small molecule being developed by Bayer AG. The drug is administered as an injection into the vein to improve the visibility of structures during MRI scans.
Gadoquatrane 0.03 mmol Gd/kg is developed by Bayer AG, a pharmaceutical company traded under the ticker BAYRY. The drug is being studied for use in contrast enhancement in magnetic resonance imaging.
Gadoquatrane 0.03 mmol Gd/kg is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for contrast enhancement in magnetic resonance imaging.
Gadoquatrane 0.03 mmol Gd/kg has one completed clinical trial, identified as NCT06135181. This Phase 1 study evaluated the safety and blood levels of BAY1747846, given as an injection into the vein at increasing single doses in Chinese healthy male participants.
Yes, Gadoquatrane 0.03 mmol Gd/kg is also known as BAY1747846. The clinical trial NCT06135181, which studied this drug, used the name BAY1747846 to refer to the investigational agent being evaluated for contrast enhancement in magnetic resonance imaging.